Most cited papers from Fractyl (United States)

Fractyl (United States)

What are the most cited papers from Fractyl (United States)?

The most cited paper from Fractyl (United States) is "Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study" (Harith Rajagopalan, Alan D. Cherrington, Christopher C. Thompson et al., 2016), with 214 citations. Next come "Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors" (184) and "Drinkable in situ-forming tough hydrogels for gastrointestinal therapeutics" (121).

Published TypeFieldAccessCitations

Showing 27 of 27 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study Harith Rajagopalan, Alan D. Cherrington, Christopher C. Thompson et al. · Diabetes Care	12 Aug 2016	214
2	Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors Alex Abramson et al. · Nature Biotechnology Open access	30 Aug 2021	184
3	Drinkable in situ-forming tough hydrogels for gastrointestinal therapeutics Gary W. Liu et al. · Nature Materials Open access	27 Feb 2024	121
4	Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial Geltrude Mingrone et al. · Gut Open access	17 Feb 2021	117
5	Age and sex in drug development and testing for adults Cara Tannenbaum, Danielle E. Day · Pharmacological Research Open access	26 Apr 2017	86
6	Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting Rehan J. Haidry, Annieke C. Van Baar, Manoel Galvão Neto et al. · Gastrointestinal Endoscopy Open access	29 Mar 2019	66
7	Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results Annieke C.G. van Baar, Ulrich H. Beuers, Kari E. Wong et al. · JHEP Reports Open access	5 Nov 2019	53
8	Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study) Annieke C.G. van Baar et al. · Diabetes Research and Clinical Practice Open access	13 Jan 2022	44
9	Hydrothermal Duodenal Mucosal Resurfacing Alan D. Cherrington, Harith Rajagopalan, DAVID G. MAGGS et al. · Gastrointestinal Endoscopy Clinics of North America Open access	11 Mar 2017	44
10	Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes Alia Hadefi, Vincent Huberty, Arnaud Lemmers et al. · Digestive Diseases	2018	26
11	Insulin sensitivity and beta cell function after duodenal mucosal resurfacing: an open-label, mechanistic, pilot study Celine B.E. Busch, Suzanne Meiring, Annieke C.G. van Baar et al. · Gastrointestinal Endoscopy Open access	25 Jan 2024	21
12	A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes Jonah A. Hoyt, Emily Cozzi, David A. D’Alessio et al. · Diabetes Obesity and Metabolism Open access	4 Mar 2024	19
13	Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism Jason A. West, Anastasia Tsakmaki, Soumitra S. Ghosh et al. · PLoS ONE Open access	31 Mar 2021	15
14	Hydrothermal duodenal mucosal resurfacing: a novel procedural therapy for metabolic disease Manoel Galvão Neto, Leonardo L. Rodriguez, Pablo Becerra et al. · VideoGIE Open access	Sep 2016	12
15	Bariatrics and endoscopic therapies for the treatment of metabolic disease: Past, present, and future Geltrude Mingrone, Harith Rajagopalan · Diabetes Research and Clinical Practice Open access	3 Apr 2024	8
16	Peptide-based GIP receptor inhibition exhibits modest metabolic changes in mice when administered either alone or combined with GLP-1 agonism Jason A. West, Soumitra S. Ghosh, David G. Parkes et al. · bioRxiv (Cold Spring Harbor Laboratory) PreprintOpen access	29 Oct 2019	3
17	Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs Timothy J. Kieffer, Christopher D. Thompson, Jacques Wainer et al. · Metabolism	31 May 2025	2
18	SINGLE-DOSE GLP-1-BASED PANCREATIC GENE THERAPY PRODUCES SUSTAINED LOWERING OF BLOOD GLUCOSE AND BODY WEIGHT IN MURINE MODELS OF DIABETES AND OBESITY T.J. Kieffer, Annette L. Fitzpatrick, C. Lubaczeuski et al. · Cytotherapy	22 May 2024	2
19	AAV-Mediated Pancreatic Gene Therapy for Type-2 Diabetes Alice P. Liou, Niharika Khanna, Jacques Wainer et al. · Metabolism	May 2023	1
20	The immunogenicity database collaborative: a standardized, publicly available database for clinical immunogenicity observations and insights Sudhanshu Agnihotri, Bruno Gonzalez-Nolasco, Brinda Monian et al. · Frontiers in Immunology Open access	30 Jun 2026	0
21	Endoscopic Ultrasound-Guided Delivery of Single-Dose Glucagon-like Peptide-1 Pancreatic Gene Therapy: Feasibility and Safety in a Porcine Model J Bergman et al. · Endoscopy	Jun 2026	0
22	Two-Year Duodenal Mucosal Resurfacing Metabolic and Patient-Reported Outcomes: German Type 2 Diabetes Real-World Registry S Martin, T Veiser, J Fitzgerald et al. · Diabetologie und Stoffwechsel Conference paper	May 2026	0
23	A moonshot for diabetes and obesity Linda S. Lee, Jay L. Caplan, Harith Rajagopalan · iGIE Open access	4 Oct 2025	0
24	A prospective post-market clinical follow-up registry to evaluate real-world effectiveness and patient satisfaction after duodenal mucosal resurfacing in patients with type 2 diabetes Torsten Beyna, T Veiser, Hui Zhang et al. · Zeitschrift für Gastroenterologie	Sep 2024	0
25	Single-dose GLP-1-based Pancreatic Gene Therapy Maintains Weight Loss After Semaglutide Withdrawal in a Murine Model of Obesity Alice Liou Fitzpatrick, Suya Wang, Emily Cozzi et al. · Metabolism	Jun 2024	0
26	A prospective post-market clinical follow-up registry to evaluate real-world effectiveness of duodenal mucosal resurfacing in patients with type 2 diabetes Stéphan Martin, Thomas Veiser, Emily Cozzi et al. · Diabetologie und Stoffwechsel	Apr 2024	0
27	OR30-07 Mixed Meal Tolerance Test (MMTT) Results from Revita-2, the First Randomized, Sham-Controlled, Double-Blind, Prospective, Multicenter Study of Duodenal Mucosal Resurfacing (DMR) Safety and Efficacy in Patients with Sub-Optimally Controlled Type 2 Diabetes (T2D) David Hopkins, Geltrude Mingrone, Guruprasad Padur Aithal et al. · Journal of the Endocrine Society Open access	Apr 2020	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.